Assessing Dupilumab Acceptability Requires Accounting for Treatment Discontinuation
Fatih Kaplan
Australasian Journal of Dermatology
· Wiley
· 2026-09-21
· DOI: 10.1111/ajd.70217
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Fatih Kaplan. Assessing Dupilumab Acceptability Requires Accounting for Treatment Discontinuation. // Australasian Journal of Dermatology. – 2026. – DOI: 10.1111/ajd.70217. – URL: https://onlinelibrary.wiley.com/doi/10.1111/ajd.70217?af=R
Fatih Kaplan (2026). Assessing Dupilumab Acceptability Requires Accounting for Treatment Discontinuation. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70217
Fatih Kaplan. “Assessing Dupilumab Acceptability Requires Accounting for Treatment Discontinuation.” Australasian Journal of Dermatology, 2026. doi:10.1111/ajd.70217.
@article{Kaplan2026,
title = {Assessing Dupilumab Acceptability Requires Accounting for Treatment Discontinuation},
author = {Kaplan, Fatih},
journal = {Australasian Journal of Dermatology},
year = {2026},
doi = {10.1111/ajd.70217},
url = {https://onlinelibrary.wiley.com/doi/10.1111/ajd.70217?af=R}
}